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1. Introduction 
Phenolic compounds (PCs) are plant secondary metabolites that are integral part of the 
“normal” human diet. The daily intake of PCs depends on the diet but is commonly 
evaluated at ca. 1g/day for people who eat several fruits and vegetables per day (Scalbert & 
Williamson, 2000). PCs may be interesting to prevent the development of inflammatory 
diseases, more particularly in the gastrointestinal tract, where their concentration may reach 
levels of up to several hundred µM (Scalbert & Williamson, 2000). Many studies have 
indeed reported on anti-inflammatory properties of different PCs (see (Calixto et al., 2004; 
Rahman et al., 2006; Romier et al., 2009; Shapiro et al., 2009), for reviews). 
Pomegranate (Punica granatum L.) belongs to the Punicaceae family, which includes only two 
species. More than 500 cultivars of Punica granatum exist with specific characteristics such as 
fruit size, exocarp and aril color, etc. Originating from the Middle East, pomegranate is now 
widely cultivated throughout the world, and also widely consumed. Pomegranate has been 
used for centuries in the folk medicine of many cultures. As described in the review of 
Lansky et al. (2007), the bark and the roots are believed to have anthelmintic and vermifuge 
properties, the fruit peel has been used as a cure for diarrhea, oral aphthae, and as a 
powerful astringent, the juice as a blood tonic, and the flowers as a cure for diabetes mellitus. 
Numerous investigations have highlighted the anti-inflammatory potential of the PCs found 
in this fruit, and more especially of hydrolysable tannins called ellagitannins (ETs), which 
are mainly located in pomegranate peels. These ETs are extracted into the juice upon 
commercial processing of the whole fruit (Gil et al., 2000). 
This chapter first describes the PCs found in pomegranate fruit, then focuses on ETs in 
relation to their metabolic fate after ingestion as well as to their anti-inflammatory 
properties on the intestine, and finally discusses gut microflora modifications following 
pomegranate ingestion and their impact on intestinal inflammation. 
2. Phenolic compounds identified in the pomegranate fruit 
The pomegranate fruit is a berry of 5 to 12 cm diameter with a leathery, deep red peel (husk, 
rind, and pericarp are synonyms). The fruit’s interior is separated by membranous walls 
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into compartments containing arils filled with pulp. Each aril contains one angular seed. 
PCs are present in different parts of pomegranate plants; they are found in seeds, arils, fruit 
peels, leaves, flowers, tree bark, and roots (Lansky & Newman, 2007). Here, we will be 
focusing on the PCs of the pomegranate fruit since the commercial processing of the whole 
fruit is largely used in the juice industry. Different classes of PCs are found in the 
pomegranate fruit. The amounts of each PC are largely affected by the raw material, e.g. 
pomegranate cultivars and climatic conditions during fruit maturation and ripening 
(Borochov-Neori et al., 2009), but also by the post-harvest storage, and the technological 
treatments leading to juice production and distribution (Tomás-Barberan et al., 2000).  
One important component of pomegranate PCs is ellagic acid (EA) (Figure 1). EA can be 
found in its free form (aglycone form), in a conjugated form with a glycoside moiety or more 
commonly complexed in the form of ETs. The occurrence of the free form in the nature is 
however quite uncommon (Clifford & Scalbert, 2000).  
 
Fig. 1. Chemical structures of EA (1) and punicalagin (2) (Lansky & Newman, 2007). 
Regarding pomegranate juice production, the phenolic profile has been reported to be very 
different if made from isolated arils only or from the whole fruit (Gil et al., 2000). In the same 
study, commercial pomegranate juices, made by pressing the whole fruit, were reported to 
show an antioxidant activity three times higher than red wine and green tea infusion, while 
hand-pressed pomegranate juice showed a lower antioxidant activity. This difference was 
attributed to the elevated amount of pomegranate peel ETs that are transferred into the juice 
during whole fruit pressing. Numerous studies have highlighted that commercial 
pomegranate juices present a very high antioxidant activity, mainly attributed to their high 
content in ETs and more particularly in punicalagin (Figure 1), which offers more than 50% 
of the total antioxidant activity (Gil et al., 2000; Li et al., 2006; Schubert et al., 1999; Seeram et 
al., 2005a; Tzulker et al., 2007).  
Given the wide difference in antioxidant activity observed with the two methods of juicing, 
it is useful to distinguish PCs found in juice made from the arils only, from those identified 
in the peel. Hydroxybenzoic acids were mainly found in the arils, except for gallic acid that 
was present at a higher level in the peel (Amakura et al., 2000; Fischer et al., 2011). 
Hydroxycinnamic acids are identified only in the arils, except for free caffeic acid and 
chlorogenic acid that were reported to be present only in the fruit peels (Amakura et al., 
2000; Fischer et al., 2011; Lansky & Newman, 2007). Among the flavonoids, luteolin and 
luteolin 7-O-glucoside (flavones), as well as naringenin 7-O-rutinoside (flavanones), 
catechin, epicatechin and epigallocatechin 3-gallate (flavanols), and quercetin, kaempferol, 
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rutin, kaempferol 3-O-glucoside and kaempferol 3-O-rhamnoglycoside (flavonols), were 
also exclusively identified in the fruit peel (Lansky & Newman, 2007; de Pascual-Teresa et 
al., 2000), whereas the flavonol dihydrokaempferol-hexoside was identified in the arils, but 
not in the peel (Fischer et al., 2011). Still in the class of flavonoids, the pomegranate fruit 
contains a collection of different anthocyanins (delphinidin 3,5-diglucoside, delphinidin 3-
glucoside, cyanidin 3-glucoside, cyanidin-pentoside-hexoside, cyaniding 3-rutinoside, 
cyaniding 3-pentoside, cyanidin 3-hexoside, cyanidin 3,5-diglucoside, pelargonidin 3-
glucoside, pelargonidin 3,5-diglucoside), which are present in both arils and peels in similar 
concentrations (Fischer et al., 2011). Pomegranate fruits are very rich in hydrolysable 
tannins,  including gallotannins and ETs, essentially present in the peel with about 44g/kg 
of dry matter of that material (Fischer et al., 2011). Gallotannins represent less than 0.01% 
and less than 2% of total hydrolysable tannins, respectively in the peel and in the juice made 
from arils only. ETs are predominantly found in the peel, with about 20 components 
identified (Fischer et al., 2011). As indicated before, the most abundant ET is punicalagin 
with a concentration of about 10.5 g/kg of dry matter of pomegranate peel, and its levels 
can be superior to 2g/L in industrial juice (Amakura et al., 2000; Borges et al., 2010; Fischer et 
al., 2011; Lansky & Newman, 2007; Martin et al., 2009, Seeram et al., 2005b).  
3. Metabolic fate of pomegranate ellagitannins 
In order to evaluate the health effects of ETs, it is critical to understand their oral 
bioaccessibility from the pomegranate matrix as well as their bioavailability.  
3.1 Bioaccessibility and intestinal absorption 
After ingestion, PCs may undergo changes until they reach the site where they could have 
an impact. In the gastro-intestinal tract, PCs are submitted, on one hand, to abiotic physico-
chemical changes and enzymatic attacks, accompanying the digestion in the upper part of 
the tract, and, on the other hand, to biotic changes with the participation of the gut 
microflora found in the lower part of the tract, and especially in the colon.  
Concerning the abiotic changes, an in vitro simulated gastric digestion showed that ETs are 
quite stable under acidic conditions and are not hydrolyzed by stomach enzymes, while an 
important increase of free EA was observed in the duodenal digestion conditions (Gil-
Izquierdo et al., 2002). Similarly, in the duodenal conditions, a significant release of EA from 
the standard punicalagin was also reported by Larrosa et al. (2006b) and it was assumed to 
be due to a spontaneous hydrolysis of punicalagin in the neutral pH conditions. When 
pomegranate juice was submitted to both in vitro gastric and duodenal digestions, no 
significant differences in total soluble phenolic contents (determined by the Folin-Ciocalteu) 
were noticed before and after gastric digestion, while, after duodenal digestion, 29% of the 
total initial phenolic content in a soluble form were available for absorption (Perez-Vicente 
et al., 2002). These results confirm that pomegranate PCs undergo modifications under 
duodenal conditions. To our knowledge, no other data are available on the fate of ETs or EA 
with reference to abiotic changes, related to enzymatic attacks and pH variations, 
encountered in the gastro-intestinal tract. In the lower part of the gastro-intestinal tract, ETs 
seem to be transformed by the gut microflora (i.e. biotic changes). An in vivo study 
conducted on pigs showed that EA, resulting from ET hydrolysis, is metabolized by the gut 
microflora that is already active in the jejunum and much more concentrated in the colon. 
This progressive metabolic processing is illustrated in Figure 2. Urolithins D, C, A and B are 
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sequentially produced, by successive losses of hydroxyl groups, resulting in an increased 
lipophilicity as well as in an increased intestinal absorption rate (Espín et al., 2007). When 
rats fed with punicalagin at a daily rate ranging from 0.6 to 1.2 g for 37 days, their feces 
showed an increased presence of punicalagin and its hydrolysis products (punicalin, 
gallagic acid, and EA) up to day 18. Afterwards, a decrease of punicalagin and punicalin 
amounts was observed concomitantly with an increase in urolithin acompounds (Cerdá et 
al., 2003b). Human fecal samples from 6 healthy volunteers were incubated with EA, 
punicalagin and an extract of walnut (rich in ETs) to search for the occurrence of urolithin A. 
Samples were analyzed at 5, 24, 48, and 72h of incubation. Urolithin A in its aglycone form 
was identified in all the samples collected, but not urolithin A conjugates, suggesting that 
the aglycones should first be absorbed before being metabolized in the conjugated forms by 
the intestinal cells and/or liver (Cerdá et al., 2005). In another study, the occurrence of the 
different urolithins (Figure 2) in their aglycone form was analyzed after incubation of 
pomegranate by-products with human fecal samples obtained from three healthy 
volunteers. The four urolithins D, C, A and B were identified (Bialonska et al., 2010). 
 
 
Fig. 2. Metabolism of pomegranate ETs by the human intestinal microflora (adapted from 
Espín et al. (2007)). 
Concerning the intestinal absorption, EA was shown to enter into the intestinal cells and to 
be further metabolized in dimethyl EA conjugates (e.g. dimethyl EA glucuronides and 
dimethyl EA sulphates) in an in vitro study using proliferating Caco-2 cells, suggesting the 
involvement of phase II enzymes (methylation, glucuronidation and sulphation) (Larrosa et 
al., 2006b). In another in vitro study (Whitley et al., 2003), with differentiated Caco-2 cells in a 
bicameral system, labeled standard EA was incubated in the apical compartment to evaluate 
its trans- or para-cellular transport. Cellular uptake seemed very extensive and probably 
governed by passive diffusion at the apical side. However, the passage across the epithelial 
cell monolayer appeared very limited since the quantity of EA found in the basolateral 
compartment was very low in this model. In accordance with this observation, a preferential 
apical efflux of EA was observed even though the multidrug resistance-associated protein 2 
(MRP2) and the P-glycoprotein, two apical efflux transporters expressed in Caco-2 cells, 
were not involved. In addition, intracellular binding processes were shown to decrease EA 
passage. Once in the intestinal cells, EA appeared indeed to bind irreversibly to DNA and 
proteins (Whitley et al., 2003), as it was already demonstrated for the flavonoid quercetin 
(Walle et al., 2003). The high irreversible binding ability of EA to DNA did not require prior 
oxidation and may be due to its great ability to intercalate DNA (Dixit & Gold, 1986; Teel et 
al., 1987; Thulstrup et al., 1999). In contrast, the covalent binding ability of EA to proteins 
www.intechopen.com
The Use of Pomegranate (Punica granatum L.) Phenolic  
Compounds as Potential Natural Prevention Against IBDs 
 
279 
may require its prior oxidation by reactive oxygen species that could be abolished by 
glutathione (Whitley et al., 2003). In the in vivo study on pigs mentioned above (Espín et al., 
2007), ET metabolites were shown to be absorbed in the intestinal tissues. The metabolites 
detected in the pig jejunum tissues were, in increasing amounts, urolithin D, urolithin C, 
urolithin A, urolithin A glucuronide, and urolithin C methyl ether, following the increase 
degree of lipophilicity. By contrast, EA conjugates were not detected in the intestinal tissues 
but were present in bile and in urines, suggesting EA absorption in the stomach. The colon 
tissues were also analyzed and only small amounts of urolithins A and B were detected. The 
results of these in vitro and in vivo studies indicate that the resulting products of microbial 
transformation, namely the urolithins, are absorbed along with EA and further metabolized 
in the enterocytes by phase II (methylation, glucuronidation and sulphation) enzymes. 
3.2 Blood circulation, distribution and excretion 
Except for the studies of Cerdá et al. (2003a & 2003b) reporting trace amounts of 
punicalagin in rat plasma after a high daily consumption of 0.9 g punicalagin for 37 days, 
many in vivo animal studies indicate that ETs are not found as such in the blood 
circulation (Borges et al., 2007; Cerdá et al., 2004a & 2004b; Espín et al., 2007; González-
Barrio et al., 2010; Mertens-Talcott et al., 2006; Seeram et al., 2006). In their pig study, Espín 
et al. (2007) reported that animals fed with acorns rich in ETs and EA (single feeding) 
showed the occurrence of urolithin A and B as aglycone and conjugates in their plasma 
24h, but not 3h, after ingestion. The same ET metabolites were also detected in trace 
amounts in the 24h urines. These observations indicate that pigs are able to produce 
rapidly the microflora metabolites (24h after a single ingestion), in contrast with rats that 
needed several days (Cerdá et al., 2003b). In pigs regularly fed with acorns and after a 24h 
fasting period, urolithins A and B as aglycone and as conjugates and EA conjugates were 
detected in both plasma and urines as well. The bile content of these animals, after gall 
bladder removal, showed a wide range of urolithins (urolithin A, C and D) conjugates, 
mainly the glucuronides, as well as EA conjugates, while no urolithin B aglycone and/or 
conjugates were found. The metabolites found in the bile coincide with those found in the 
lumen, except for the aglycone EA that was not detected in the bile. The presence of a 
wide range of ET metabolites in the bile and the very low clearance of these compounds  
in urines suggested an important enterohepatic circulation (Espín et al., 2007). 
Interestingly enough, the study of Cerdá et al. (2003b) on rats fed with punicalagin for  
37 days did not only report on fecal analyses (see section 3.1), but also on plasma and 
urine levels of ET metabolites. They showed that, during a first period of about 20  
days, the main metabolites detected in plasma and urines were derived only from 
punicalagin hydrolysis through conjugation in methyl ether or glucuronide forms, 
whereas, after 20 days, urolithins and their glucuronides were detected, which may be 
due, as for the fecal observations, to a modification of the gut microflora composition. 
After mice ingested a single dose (0.8 mg per animal) of an ET-enriched pomegranate peel 
extract, standardized to 37% ETs and 3.5% EA, plasma samples were collected over 24h. 
EA was detected in the plasma 30 min after pomegranate extract ingestion and was 
cleared after 2h, while neither urolithin A nor urolithin A conjugates were detected 
during the 24h (Seeram et al., 2007). The pharmacokinetics of EA was evaluated after oral 
administration of a pomegranate leaf extract to rats. A rapid increase of EA was observed 
in the plasma with a maximum concentration reached 0.54h after ingestion and a plasma 
half-life of 5h (Lei et al., 2003).  
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Human studies on healthy volunteers seem to confirm the results obtained in animal 
studies. A first trial was conducted on one subject who ingested 180 mL of pomegranate 
juice containing 25 mg of EA and 318 mg of ETs. In order to evaluate EA bioavailability, 
blood samples were collected until 6h after consumption. A maximum concentration was 
detected 1h post-ingestion and EA was cleared after 4h (Seeram et al., 2004). On the basis of 
that preliminary study, another study was performed on 18 healthy human volunteers who 
consumed 180 mL of pomegranate juice containing 1561 mg/L of punicalagin, 121 mg/L of 
EA, and 417 mg/L of other ETs. Blood samples were analyzed during the 6h following 
ingestion and urines were collected in 12h batches the day before, the day of, and the day 
after ingestion. Again, no ETs were detected as intact form in plasma. By contrast, EA could 
be detected. It peaked at 0.98±0.06 h post-ingestion (Tmax), with a maximum concentration 
(Cmax) of 0.06±0.01 µmol/L (18.64 ng/mL), and an elimination half-life (T1/2) of 0.71±0.08 h. 
It was cleared within 5h. The area under the curve (AUC) was 0.17±0.02 (µmol*h)*L-1 (50.07 
ng*h/mL). Interestingly, urolithin A and B as aglycone and as conjugates began already to 
appear in blood collected 0.5h after ingestion and higher concentrations were found in 6h 
plasma samples. EA and dimethyl EA glucuronide were detected in urines of the day of 
juice consumption, respectively for 5 and 15 of the 18 subjects, but not of the following day. 
Urolithin A and B glucuronides appeared in the urines collected the second 12h of the day 
of the study, and in the urines collected the day after (Seeram et al., 2006). After 6 healthy 
volunteers ingested 1 L of pomegranate juice per day for 5 days, the occurrence of 
metabolites in plasma and urines was examined (Cerdá et al., 2004a). Neither punicalagin 
nor EA, in free or in conjugated form, was found in plasma samples, whereas urolithins 
conjugates were detected (urolithin A glucuronide, an unidentified aglycone metabolite and 
urolithin B glucuronide). The urines revealed the presence of 3 additional microflora 
metabolites (urolithin A, urolithin B, and an unidentified aglycone metabolite). The 
metabolites found in plasma and urines presented high inter-individual variability (Cerdá et 
al., 2004a). Another study conducted on 40 healthy volunteers investigated the metabolic 
fate of ETs from 4 different sources of ET-rich foodstuffs, i.e. strawberries, red raspberries, 
walnuts, and oak-aged red wine. Each group of 10 volunteers received a single dose of ET-
containing foodstuff and the urines were collected in 5 fractions, at 8, 16, 32, 40, and 56h 
after food intake (Cerdá et al., 2004b). As previously observed with pomegranate juice 
consumption (Cerdá et al., 2004a), neither ETs nor EA were detected in none of the urine 
fractions collected. Whatever the foodstuff ingested, urolithin B glucuronide was detected in 
all the urines from 32h to 56h following ingestion, and urolithin B in some of them (Cerdá et 
al., 2004b). In another human study, 2 capsules corresponding to 800 mg of pomegranate 
extract (330.4 mg of punicalagin and 21.6 mg of EA), were administered to 11 healthy 
volunteers. No punicalagin was found in human plasma, while EA appeared in plasma with 
similar pharmacokinetic parameters as previously observed: Tmax=1h, Cmax=33.8±12.7 
ng/mL, T1/2=0.94h and AUC=118.01 ng*h/mL. The microflora metabolites were detected as 
well (e.g. urolithin A, hydroxyl urolithin A, urolithin A glucuronide, urolithin B and 
dimethyl urolithin B glucuronide). Again, these different metabolites were not present in all 
the subjects tested, which could be explained by the difference in microflora composition 
responsible for ET degradation (Mertens-Talcott et al., 2006). A single intake of raspberry 
containing ETs was given to 10 healthy humans and 4 humans with ileostomy. Blood was 
collected during 24h and urines were collected at 4, 7, 24 and 48h post-ingestion. Urolithins 
were detected in the plasma of the healthy volunteers, but not in the plasma of the patients 
with ileostomy, confirming that urolithins are formed in the large intestine. No ETs in an 
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intact or conjugated form were detected in the plasma of any subjects during 24h after 
raspberry intake. Small amounts of EA and EA glucuronide were detected in the urines 
from both groups. However, urolithin A and B glucuronides were only identified in the 
urines of healthy subjects collected at 7 to 48h post-ingestion (González-Barrio et al., 2010). 
In sum, these human studies indicate that there is no absorption of the ETs in an intact form.  
Concerning the distribution in non-intestinal tissues, an in vitro study reported that 
urolithins A and B entered into the human breast cancer MCF-7 cells and were metabolized 
in urolithin sulphate and glucuronide conjugates (Larrosa et al., 2006a). In the mice study of 
Seeram et al. (2007), prostate, liver, kidney, lung and brain tissues were analyzed 24h after 
pomegranate extract ingestion. Neither EA, nor ETs, nor urolithin A in free or conjugated 
form was detected in any tissues when pomegranate was orally administrated. In the pig 
study performed by Espín et al. (2007), liver, kidney, heart, lung, brain, and muscle tissues 
were analyzed after a 117 day-ET rich diet, and again no ET metabolites were detected. 
Nevertheless, in the rat study performed by Cerdá et al. (2003a), 5 punicalagin metabolites 
(two EA conjugates, gallagic acid, urolithin A glucuronide, and urolithin C glucuronide) 
were detected in the two organs investigated, namely liver and kidney.  
 
 
Abbreviations: conj., conjugates ; EA, ellagic acid; ETs, ellagitannins; UROs, urolithins. 
The compounds in green result from a microbial action on EA. 
Fig. 3. Model of the metabolic fate of ellagitannins and ellagic acid in the human intestine. 
As summarized in Figure 3, upon ingestion of pomegranate, ETs seem to be partially 
hydrolyzed in the upper part of the gastrointestinal tract to release EA that is further 
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metabolized by the colon microflora to form the bioavailable urolithins. Free EA found in 
pomegranate could already be absorbed in the small intestine epithelial cells, while intact 
ETs need to reach the large intestine where they are shown to be extensively transformed in 
urolithins by the intestinal microflora before being absorbed. Once urolithins and EA are 
absorbed, they are conjugated to give methyl ether, glucuronide or sulphate conjugates by 
phases II enzymes. These conjugates can be found in the plasma, as well as in the intestinal 
lumen, directly after conjugation in the intestinal cell, or via the enterohepatic circulation. 
Part of them is not absorbed and is excreted in the feces. The urolithins and EA, either 
conjugated or in their free form, can temporarily accumulate in the intestinal tissues before 
being liberated in the plasma. 
4. Effects of pomegranate phenolic compounds on the intestinal 
inflammatory response in IBD-related models 
Since the last years, anti-inflammatory effects related to pomegranate consumption were 
reported in intestinal in vitro and in vivo studies, suggesting a role for pomegranate-
derived products in IBD prevention. Causes of IBDs are not well known but two main 
hypotheses are put forward. The first hypothesis suggests that a deregulation of the 
mucosal immune system provokes excessive immunologic responses against the normal 
gut microflora, while the second one proposes that changes in the composition of the gut 
microflora associated with a disrupted epithelial barrier lead to an abnormal 
inflammatory response from the intestinal mucosa (Stecher & Hardt, 2008). In this section, 
in vitro and in vivo studies highlighting the anti-inflammatory properties of pomegranate 
PCs will be reviewed.  
4.1 In vitro anti-inflammatory effects of pomegranate phenolic compounds 
Anti-cancer effects of pomegranate have been described in in vitro studies on cell 
proliferation and apoptosis using human colon cancer cells (Larrosa et al., 2006b; Seeram et 
al., 2005b). Even if IBDs are associated with increased risk for colorectal cancer and if there 
are similarities in the biology of IBD-associated colon cancer and sporadic cancer (Rhodes & 
Campbell, 2002), these highlighted effects are not, strictly speaking, related to the intestinal 
inflammation response developed by IBD patients, and therefore, will not be detailed in this 
section. Among in vitro studies on intestinal epithelial cells, only three studies investigated 
the intestinal anti-inflammatory potential of pomegranate extracts, pomegranate juice or 
pomegranate PCs. They were carried out on human colon epithelial cells: Caco-2 cells 
(Romier-Crouzet et al., 2009; Sergent et al., 2010) and HT-29 cells (Adams et al., 2006). In 
these studies, intestinal inflammation was induced either by IL-1β (Romier-Crouzet et al., 
2009), or TNF-α (Adams et al., 2006) or by a mixture of pro-inflammatory molecules, i.e. IL-
1β, IFN-γ, TNF-α and LPS (Romier-Crouzet et al., 2009; Sergent et al., 2010). Additional in 
vitro studies have evaluated the potential role of pomegranate for preventing IBDs by using 
other types of cells involved in the intestinal immune response, such as murine splenic 
lymphocytes CD4+ T cells (S.I. Lee et al., 2008), RAW 264.7 murine macrophages (C.J. Lee et 
al., 2010; Panichayupakaranant et al., 2010), or the human basophilic cell line KU812 
(Rasheed et al., 2009). In these studies, inflammation was induced either by LPS (C.J. Lee et 
al., 2010; Panichayupakaranant et al., 2010) or by phorbol-12-myristate 13-acetate plus 
calcium ionophore A23187 (PMACI) (Rasheed et al., 2009).  
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4.1.1 In vitro effects on inflamed intestinal cells 
Ellagic acid. Anti-inflammatory effects of EA were evaluated by measuring inflammatory–
related cytokine (the pro-inflammatory cytokines IL-6, IL-8, MCP-1 and the anti-
inflammatory IL-10) secretion and mRNA expression in differentiated Caco-2 cells 
stimulated with the pro-inflammatory cocktail (IL-1β, IFN-γ, TNF-α and LPS) (Sergent et al., 
2010). For the experiments, cells were seeded on a microporous membrane in bicameral 
inserts. Two-day treatments were started at day-19 by adding EA (50 µM final 
concentration) to the apical side of the cells, while the cocktail of pro-inflammatory stimuli 
was concomitantly introduced to the basolateral side. The amounts of pro-inflammatory 
cytokines were quantified with ELISA assays after pooling the media from both 
compartments. EA decreased MCP-1 and IL-8 secretion but not significantly, and had  
no effect on IL-6 and IL-10 secretions, while mRNA expression of the four cytokines was  
not affected. Nevertheless, in that study, EA down-regulated the transcription of three  
genes involved in the intestinal inflammation: CD14 (Cluster of differentiation 14 gene) 
encoding a protein acting as LPS receptor, IL1R1 (Interleukin 1 receptor type 1 gene),  
and PLA2G2A (phospholipase A2 gene). EA also significantly down-regulated the 
transcription factor STAT3 (signal transducer and activator of transcription 3) involved  
in the persistent activation of NF-κB (the nuclear factor-kappa B), an inducible  
nuclear transcriptional factor associated with the intestinal inflammatory response (Yu et al., 
2009) and the gene CYP1A1 (Cytochrome P450, family 1, subfamily A, polypeptide 1) 
(Sergent et al., 2010). 
Pomegranate peel extract. A pomegranate peel extract, used at the concentration of 50 µM 
gallic acid equivalent (GAE), was reported to inhibit NF-κB activity in confluent Caco-2 cells 
temporarily transfected with a NF-κB-luciferase construct and under IL-1β stimulation. The 
same extract tested on Il-1β-stimulated and non-transfected confluent Caco-2 cells was also 
found to inhibit slightly Erk1/2 phosphorylation, but had no effect on JNK phosphorylation 
(2 major members of the mitogen-activated-protein kinase (MAPK) cascades involved in the 
intestinal inflammatory response). In addition, it significantly decreased IL-8 secretion as 
well as cyclooxygenase-2 (COX-2) activity, as measured by the synthesis of prostaglandin-E2 
(PGE2) upon incubation of the cells with arachidonic acid (Romier-Crouzet et al., 2009).  
 Pomegranate juice, tannins and punicalagin. Effects of pomegranate juice, total pomegranate 
tannins and punicalagin on inflammatory proteins involved in cell signaling cascades were 
evaluated using HT-29 colon cancer cells stimulated with TNFα. The juice was commercially 
available (POM Wonderful LLC, Los Angeles, CA) and was used in a concentrated form 
containing 1.74 g/L punicalagin, while purified punicalagin as well as total pomegranate 
tannins were isolated from the fruit peel and normalized at equivalent concentrations of 
those found in the juice. The induced COX-2 protein expression was decreased with all the 
three preparations, in a dose dependent manner. In addition, the pomegranate juice was 
shown to significantly inhibit the protein kinase B (AKT) activity, which is known for 
increasing COX-2 expression (Adams et al., 2006).  
4.1.2 In vitro effects on immune cells 
Other pomegranate anti-inflammatory properties have been highlighted not directly on the 
intestinal epithelial cells but also on immune cells since both cell types are interacting 
during the intestinal inflammatory response. 
Macrophage cells. In inflammatory events, macrophage cells, stimulated by the pro-
inflammatory cytokines secreted by the activated T cells, produce in turn a large amount of 
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pro-inflammatory mediators (e.g. TNFα, interleukins, and reactive oxygen species (ROS)). 
RAW 264.7 murine macrophages were used to study the anti-inflammatory properties of 4 
ETs isolated from pomegranate peels, namely punicalagin, punicalin, strictinin A, and 
granatin B (C.J. Lee et al., 2010). Inflammation was induced by 24h pre-incubation with LPS 
(1 µg/mL), leading to a high secretion of NO and PGE2 as well as to an up-regulation of 
iNOS and COX-2 protein expression. Inhibitory effects on NO production were observed for 
the 4 isolated ETs (at 100 µM) with the following decreasing order of intensity: granatin  
B > strictinin A > punicalagin > punicalin. That NO inhibition was neither due to  
NO-scavenging activity, nor to iNOS activity inhibition, but was the consequence of a 
decrease in iNOS protein expression with the strongest effect attributed to granatin B. Only 
granatin B significantly reduced PGE2 production and COX-2 expression in a dose 
dependent manner after 8h of treatment, while granatin B showed no effect on COX-2 
expression after 18h exposure (C.J. Lee et al., 2010). An inhibition of NO production was also 
found with a standardized pomegranate peel extract containing 13% w/w EA, in LPS-
induced (100 µg/mL) RAW 264.7 cells. This peel extract revealed marked anti-NO effects, 
equivalent to that of L-nitroarginine, a NO synthase inhibitor, with an IC50 (concentration at 
which 50% of the inhibitory effect is observed) of 10.7 µg/mL. Standard EA was also tested 
and revealed even higher anti-NO effects with an IC50 value of 1.9 µg/mL 
(Panichayupakaranant et al., 2010). 
Mast cells. Mast cells are other key players in the inflammation that release, upon activation, 
numerous mediators by discharging their granules and/or by synthesizing them. These 
mediators play a role by recruiting leucocytes to the inflammation site, and by activating 
many of them to produce their own mediators of inflammation. The anti-inflammatory 
potential of a standardized pomegranate fruit extract (POMx, POM Wonderful brand) has 
been evaluated on KU812 cells, a model of human mast cells, which were stimulated with 40 
nM of phorbol 12-myristate 13-acetate (PMA) plus 1 µM of calcium ionophore (CI) (Rasheed 
et al., 2009). The cells were pre-treated with POMx (20-100 µg/mL) for 1h prior to 
stimulation with PMA-CI for 4h. POMx significantly inhibited IL-6 and IL-8 secretions and 
decreased the corresponding gene expressions in a dose-dependent manner. Furthermore, 
POMx attenuated JNKp54/p46 and ERKp44/p42 phosphorylation, but had no effect on p38-
MAPK phosphorylation in PMA-CI-induced mast cells. POMx inhibited the PMA-CI-
induced degradation of IκBα and nuclear translocation of p65 NF-κB. Finally, POMx 
significantly inhibited the NF-κB DNA binding activity in KU812 cells transfected with a 
NF-κB-luciferase construct and exposed to PMA-CI (Rasheed et al., 2009). 
T cells. Naïve T cells (Th0) activation initiates an adaptive immune response, and then, plays 
a central role in the development of autoimmune diseases. In IBDs, effector T cells (Th1, Th2 
and Th17) predominate over regulatory T cells (Th3, Tr). These activated T cells secrete pro-
inflammatory cytokines (IL-4, IL-5, IL-12, IL-13, IL-17, INFγ, etc.) that stimulate 
macrophages. Punicalagin was identified as a potent immune suppressant in activated 
murine splenic CD4+ T cells. Indeed, a 24h exposure of these cells to punicalagin (5 µM) 
decreased the secretion of IL-2, a protein stimulating growth and differentiation of T cells. A 
reduction of IL-2 mRNA levels was also observed with 5 µM punicalagin (S.I. Lee et al., 
2008). Furthermore, after 6h incubation, punicalagin (2.5-40 µM) significantly inhibited the 
activation of the nuclear factor activated T cells (NFAT), a transcription factor for IL-2 
expression after T cell activation, in a dose-dependent way, in NFAT-Jurkat cells stimulated 
with PMA (10 ng/mL) and CI (1 µM) (S.I. Lee et al., 2008). 
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4.2 Ex vivo intestinal anti-inflammatory effects of pomegranate PCs  
A single dose (34 mg/kg body weight (bw)) of pomegranate fruit extract (POMx, POM 
Wonderful brand) was orally administrated to experimental rabbits. After 2h, blood samples 
of the experimental and the control groups were collected in order to test the inhibitory 
effects of plasma samples on the activities of COXs ex vivo by using purified enzyme 
preparations. Both COX-1 and COX-2 activities were reduced ex vivo in presence of the 
experimental plasma (2h post-supplementation with POMx) versus the control plasma (prior 
supplementation), with a higher effect on COX-2 activity. These results suggested that 
pomegranate fruit extract component and/or metabolites may inhibit the activity of eicosanoid 
generating enzymes, and then exert anti-inflammatory effects ex vivo (Shukla et al., 2008). 
4.3 In vivo intestinal anti-inflammatory effects of pomegranate phenolic compounds 
Although all the in vitro studies seem to show anti-inflammatory effects of the pomegranate 
fruit in intestinal inflammation, its biological activity should be proven in vivo.  
Among the in vivo studies on the effects of pomegranate PCs on intestinal inflammation 
related to IBDs, four studies conducted on murine models were reported in the literature: 
three with rats (Larrosa et al., 2010; Ogawa et al., 2002; Rosillo et al., 2011) and one with mice 
(Singh et al., 2009). Experimental models of IBD were induced by a daily oral administration 
of dextran sulphate sodium (DSS) at 2-5% (v/v) in drinking water or by intra-colonic 
administration of trinitrobenzene sulfonic acid (TNBS).  
4.3.1 Rat studies 
Ellagic acid. To evaluate the prophylactic effects of EA in the treatment of IBDs (Ogawa et al., 
2002), EA was administered to rats, as such or in an encapsulated form. The microsphere 
capsules allowed EA to reach the terminal ileum and colon where microcapsules dissolved. 
Encapsulated or not, EA was administrated orally twice daily for the last 6 days during the 7 
day treatment with DSS to one group of rats. Another DSS-induced colitis rat group 
received superoxide dismutase (SOD), a well-known anti-oxidative agent, intra-rectally 
twice daily for the last 6 days. Colonic mucosa of DSS-treated animals showed typical 
inflammatory changes such as erosions, ulcerations, and infiltration of immune cells. The 
administration of encapsulated EA (1-10 mg/kg bw) prevented the development of DSS-
induced colitis with an effective dose on 50% of rats (ED50) of 2.3 mg/kg bw. The same 
effects were observed with non-encapsulated EA, but at higher concentrations (ED50 32.9 
mg/kg bw). Treatments with EA also prevented the decrease in colon length due to DSS 
treatment, and again a higher effect was observed with the encapsulated EA. Lipid 
peroxidation in the colonic mucosa, determined by the thiobarbituric acid-reactive 
substance (TBARS) assay, was significantly decreased by the encapsulated EA treatment, 
but was not affected by free EA. Similar effects were observed after SOD administration, 
supporting the idea that EA prevents the colitis development by radical scavenging or other 
anti-oxidative actions (Ogawa et al., 2002). EA was orally administrated to rats at both doses 
(10 and 20 mg/kg bw) 48, 24 and 1h before TNBS intra-colonic administration and 24h after. 
Both doses of EA significantly decreased the extent and severity of the colonic damage and 
the leukocyte infiltration, and increased the mucus production by goblet cells. EA decreased 
COX-2 and iNOS protein expressions induced by TNBS. EA also inhibited both MAPK 
(ERK, JNK, and p38) pathways by preventing their phosphorylation and NF-κB pathway by 
preventing the IκBα degradation and the nuclear translocation of p65 in the intestinal 
epithelial cells from inflamed rat colon (Rosillo et al., 2011). 
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Pomegranate polyphenolic extract and urolithin A. A DSS-induced colitis rat model was used to 
study the anti-inflammatory effects of a commercial pomegranate extract (“Nutragranate 
from Nutracitrus S.L., Elche, Spain), and of urolithin A (see section 3). Rats received a 
standard diet for 25 days with 5% DSS for the last 5 days. The test groups received the 
standard diet supplemented either with pomegranate extract (250 mg/kg bw/day) or with 
urolithin A (15 mg/kg bw/day) (Larrosa et al., 2010). Typical histological changes of 
inflammation were observed in the colon of DSS-induced colitis rats, together with increases 
in the prostaglandin E synthase (PTGES) and COX-2 protein levels and in their catalysis 
product, namely PGE2, and with an up-regulation of iNOS mRNA expression associated 
with higher levels of NO in the colon mucosa. Urolithin A supplementation significantly 
attenuated the histological changes induced by DSS in colon mucosa, while the 
pomegranate extract showed non-significant attenuations. Both supplementations decreased 
the PTGES and COX-2 protein levels, and lowered PGE2 production in the colon mucosa 
with more efficient effects in the case of the pomegranate extract. In addition, both 
supplementations allowed to significantly decrease NO levels in colon mucosa (Larrosa  
et al., 2010). 
4.3.2 Mice studies 
Pomegranate flower extract and EA-rich fraction. The potential beneficial properties of a 
pomegranate flower extract and of its EA-rich fraction were evaluated in mice with 
ulcerative colitis induced by a daily administration of DSS (2%) in drinking water for 7 days 
(Singh et al., 2009). Treatments were administrated concomitantly with DSS and during a 
period of 48h before. Colonic tissues were harvested on the day 8 after DSS treatment for 
macroscopic and biochemical analyses. As expected, DSS administration induced mucosal 
injuries and reduced colon length. Administration of the pomegranate extract and its EA-
rich fraction significantly attenuated most of the DSS-induced macroscopic changes. Body 
weight loss, stool consistency, and bleeding, were also improved by both treatments, as well 
as the histopathological changes induced by DSS in the colon. DSS administration was also 
associated with an increase in myeloperoxidase (MPO) activity from an intense infiltration 
of neutrophils in the colon in association with an acute inflammation. A decrease of MPO 
activity in colonic tissues was also observed with both treatments. In addition, both 
treatments decreased histamine levels in colonic tissues, suggesting a prevention of 
histamine release. Finally, they also decreased the oxidative stress, measured by the TBARS 
assay, and the superoxide anion generation, which were significantly increased in DSS–
treated mice (Singh et al., 2009).  
4.3.3 Human studies 
To our knowledge, no human study has yet been conducted to evaluate anti-inflammatory 
properties of pomegranate in subjects suffering from IBDs. There is a serious need for this 
kind of studies to validate the purported beneficial effects of pomegranate-derived 
products. Nevertheless, a study conducted on healthy human subjects showed an increase 
by 6% of serum antioxidant status, 2h after consumption of a commercial pomegranate juice 
(POM Wonderful LLC, Los Angeles, CA), and by 11% after a daily consumption of 250 mL 
of that juice for 1 week (Rosenblat et al., 2010). The increment of antioxidant status and 
reduction of oxidative damage after pomegranate juice consumption were also observed in 
another study conducted on healthy elderly subjects who consumed daily 250 mL of juice 
for 4 weeks (Guo et al., 2008). In physiological inflammation, ROS are scavenged by 
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substances naturally found in our organism. However, in IBDs, the chronic pathological 
inflammatory response is characterized by an overproduction of ROS leading to persistent 
oxidative stress and to functional alterations in DNA, proteins and lipids (Bartsch & Nair, 
2006; Kapoor et al., 2005). It can thus be speculated that oxidative status improvements 
offered by the consumption of pomegranate products can attenuate IBD severity. 
5. Effects of pomegranate phenolic compounds on the gut microflora 
associated to IBD pathogenesis 
The human gut microflora is estimated to contain 1018 of microorganisms (Davis & Milner, 
2009) with about 1014 bacteria classified within 4 bacterial phyla, namely Firmicutes, 
Bacteroidetes, Actinobacteria, and Proteobacteria (Seksik, 2010). Gut microflora is composed 
of beneficial bacteria (like Bifidobacterium spp. from the Actinobacteria phylum, and 
Lactobacillus spp. from the Firmicutes phylum), but also comprises deleterious bacteria (like 
certain members of Clostridium spp. or Staphylococcus spp. from the Firmicutes phylum). 
Archae, fungi and protozoa also make up the human gut microflora but little is known 
about their activities. The gut microflora is a critical component in the development and 
prevention/treatment of IBDs and its composition differs in IBD patients compared to 
healthy patients (Swidsinski et al., 2002). Nutrients, such as PCs, may influence that 
composition by enhancing or depleting the growth of beneficial bacteria, and by increasing 
or decreasing deleterious bacteria (Laparra & Sanz, 2010). Changes of gut microflora 
composition after consumption of pomegranate PCs have thus been investigated in different 
ways. Several studies have highlighted the antimicrobial effects of pomegranate extracts or 
PCs on isolated bacteria or fungi. A pomegranate peel extract showed antimicrobial effects 
(evaluated by measuring the zone of inhibition (IZ)) against different multi-drug resistant 
pathogenic organisms according to the following decreasing order: Staphylococcus aureus, 
Salmonella paratyphi, Shigella dysenteriae > Candida albicans > Bacillus subtilis, Escherichia coli 
(Ahmad & Beg, 2001). EA, gallagic acid, punicalin, and punicalagin, which were isolated 
from a pomegranate peel extract, were also evaluated for their antimicrobial activities 
against pathogenic fungi (C. albicans, Cryptococcus neoformans, and Aspergillus fumigatus), a 
non-pathogenic strain of E. coli, and pathogenic bacteria (Pseudomonas aeruginosa and 
Mycobacterium intracellulare). EA and punicalin did not show any antimicrobial activity at 
the highest concentration tested (20 µg/ml). However, gallagic acid and punicalagin 
inhibited the growth of E. coli, P. aeruginosa, and C. neoformans with IC50 values lower than 15 
µg/mL (Reddy et al., 2007). Another study also highlighted the inhibitory effects of a 
pomegranate peel extract against antibiotic-resistant pathogenic bacteria and fungi. 
Significant inhibitory effects were observed against a pathogenic strain of E. coli, and the 
pathogenic S. aureus, B. subtilis, Listeria monocytogenes, P. aeruginosa and Yersinia enterocolitica. 
An antifungal activity was also observed against Candida utilis, Saccharomyces cerevisae, and 
Aspergillus niger (Al-Zoreky, 2009). The effects of the standardized commercial pomegranate 
peel extract POMx and of pure punicalagin, punicalin, EA, and gallic acid were evaluated 
on the growth of intestinal bacteria in liquid cultures. POMx and punicalagin inhibited the 
growth of S. aureus and of Clostridium spp.. Interestingly enough, the growths of the 
probiotic Lactobacillus spp. and Bifidobacteria spp. were relatively unaffected neither by the 
extract POMx nor by the pure polyphenols, except for the growths of the probiotics 
Bifidobacterium breve and Bifidobacterium infantis, which were significantly enhanced by 
POMx. In this study, POMx application resulted in a decrease of pH media that could 
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partially explain its inhibition towards pathogenic bacteria that are more susceptible to low 
pH than probiotic bacteria (Bialonska et al., 2009). Another pomegranate peel extract was 
evaluated for its antibacterial activity towards Propionibacterium acnes, S. aureus, 
Staphylococcus epidermidis, E. coli, Salmonella typhimurium, Salmonella typhi and Shigella sonnei. 
After exposure to pomegranate peel extract (200 mg/mL), inhibitory effects were observed 
against the deleterious gram-positive bacteria P. acnes, S. aureus and S. epidermidis, while no 
inhibitory effect was seen on the non-pathogenic gram-negative bacteria E. coli,  and on the 
pathogenic gram-negative S. typhimurium, S. typhi , and S. sonnei (Panichayupakaranant et 
al., 2010). Normal human gut microflora also contains harmless saprophyte yeasts, like 
Candida spp., in a normal gastrointestinal tract. However, if the immune defenses are 
compromised, these yeasts can cause infections. In a recent study, Candida spp. were 
incubated with punicalagin or a pomegranate peel extract (Endo et al., 2010).  
Punicalagin showed strong antifungal activities against C. albicans and Candida parapsilosis, 
while the pomegranate peel extract did not show any antifungal activity. In the same study, 
the pomegranate peel extract was also tested against E. coli, P. aeruginosa, B. subtilis, and S. 
aureus and showed inhibitory effects only against S. aureus. The antimicrobial and antifungal 
activities of pomegranate PCs are summarized in Table 1. 
The antimicrobial potential of pomegranated-derived products has also been tested in feces, 
which represent a more complex model than isolated bacteria or fungi. Bialonska et al. (2010) 
investigated the potential antibacterial activities of POMx and punicalagin on bacteria 
present in fecal samples obtained from 3 healthy human subjects without any 
gastrointestinal disease history. The samples were used to inoculate batch-culture vessels 
and both POMx and punicalagin were added under anaerobic conditions. Bacterial 
enumeration was assessed by a fluorescence in situ hybridization technique (FISH) using 
ribosomal RNA-targeted oligonucleotide probes for Bifidobacterium spp., Lactobacillus-
Enterococcus group, Clostridium coccoides-Eubacterium rectale group, Clostridium histolyticum 
group, as well as for the totality of bacteria. POMx significantly increased the number of 
Bifidobacterium spp., as well as the Lactobacillus-Enterococcus group and the total number of 
bacteria. By contrast, it did not change the growth of the commensal Clostridium coccoides-
Eubacterium rectale group and C. histolyticum group. Punicalagin had no significant effect on 
any bacteria (Bialonska et al., 2010). Another study (Larrosa et al., 2010) investigated the 
effects of Nutragranate and urolithin A (see section 3) on the gut microflora composition in 
DSS-induced colitis rats vs. control rats. Both supplementations for 10 days resulted in an 
increase of Bifidobacterium spp, Lactobacillus spp. and Clostridium spp. in the control rats. 
After DSS administration for 5 days, the increases of Bifidobacterium spp, Lactobacillus spp. 
and Clostridium spp were maintained in rats fed with urolithin A, but were reduced in rats 
eating the pomegranate extract. In addition, significant increases of E. coli, of the whole 
Enterobacteriaceae family and of total aerobic bacteria were observed in the DSS-induced 
colitis model (without any supplementation). These increases were significantly lower in the 
groups supplemented with the pomegranate extract or urolithin A. The inflammatory status 
induced by DSS generated differences in the metabolism of pomegranate PCs. As such, in 
the healthy rats eating the pomegranate extract, the expected metabolite urolithin A was 
significantly recovered in feces (190 µg/g), but not ETs or EA. In the DSS-treated rats eating 
the pomegranate extract, EA was predominant in feces, while urolithin A was detected in 
much lower quantities (8 µg/g). These differences can be put in parallel with the microbial 
effects observed and suggest that urolithin A formation in the gut lumen is an important  
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step for the pomegranate extract to affect the gut microflora composition (Larrosa et al.,  
2010). The effect of pomegranate extracts or of their derived PCs on the gut microbiota can 
occur at different levels and could partially explain their beneficial role in IBDs. First, 
tannins are known to complex enzymes, in particular those secreted by the gut microbiota, 
leading to changes in their structural conformation and thereby inhibiting their enzymatic 
activities. Furthermore, tannins might form complexes with proteins of cell walls, and by 
that way, could result in the decrease of both cell permeability and substrate transport into 
cells. Tannins may also form stable complexes with metal ions (e.g., Fe and Cu), resulting in 
the decrease of their availability to bacteria and therefore affecting the activity of their 
metalloenzymes. Finally, as already mentioned, another effect of pomegranate extracts 
could be the decrease of pH within the intestinal lumen. Most of the time, a low pH favors 
probiotic bacteria, while deleterious bacteria would be more affected by acidic conditions 
(Puupponen-Pimia et al., 2005). 
6. Conclusion 
Plant-derived secondary metabolites are the basis for many drugs or food supplements 
currently used to treat or prevent pathologic conditions. Since recent research works have 
shown that the repeated oral administration of high doses of pomegranate to rats and mice 
was not toxic (Cerdá et al., 2003a, Patel et al., 2008), it is expected that pomegranate peel 
polyphenolic extracts do not show any severe toxicity in humans. However, further 
investigations are needed to confirm its safety in humans. The pomegranate peel is a by-
product of the pomegranate juice industry that contains high amounts of ETs. When the 
pomegranate is ingested, these ETs are metabolized mainly in active urolithins by the  
gut microflora but a lower metabolization occurred in inflamed conditions. In addition to its 
high antioxidant activity, pomegranate presents anti-inflammatory properties potentially 
interesting against IBDs by acting on several mechanisms involved in the intestinal 
inflammatory response. These mechanisms include the interaction with the NF-κB  
and MAPK cascade pathways, the reduction of the mRNA expression and protein secretion 
of various pro-inflammatory cytokines, the decrease of the inducible isoforms of iNOS  
and COX-2 and their resulting products NO and PGE2, known to participate in an increase 
of the inflammatory status. It also improves the luminal microbiota composition.  
These different effects were mainly observed in in vitro models of intestinal epithelial and 
immune cells. Results generated in vivo go in the same direction, i.e. pomegranate PCs can 
decrease the inflammatory status of animals with induced-inflammation. However, the 
number of animal studies remains quite limited and to our knowledge, no one human study 
has been published yet in a peer-reviewed journal. Therefore, since increasing evidence  
in vitro and in vivo converge to indicate beneficial effects of pomegranate PCs on intestinal 
inflammation, further in vivo studies are necessary and trials on human subjects should  
be designed to investigate the pomegranate potential and especially that of pomegranate 
peel extracts on IBDs. 
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